A study led by researchers at the University of Kentucky Markey Cancer Center highlighted differences in patient diagnosis and treatment in those with non-small cell lung cancer (NSCLC) across the state of Kentucky.
Sep 23, 2020
0
0
According to a new study, mortality rates from the most common lung cancer, non-small cell lung cancer (NSCLC), have fallen sharply in the United States in recent years, due primarily to recent advances in treatment.
Aug 12, 2020
0
232
More than 200 genes with novel and known roles in glioblastoma—the most aggressive type of brain cancer—offer promising new drug targets. Researchers from the Wellcome Sanger Institute, Addenbrooke's Hospital and their ...
Jul 29, 2020
0
176
Researchers at the University of Alberta have found a way to deliver anti-cancer drugs with more precision, which could increase the effectiveness of many cancer treatments.
Jul 3, 2020
0
136
A component of breast milk may help protect premature babies from developing sepsis, a fast-moving, life-threatening condition triggered by infection. Researchers at Washington University School of Medicine in St. Louis and ...
Mar 16, 2020
0
73
Two recently approved leukemia drugs could be enlisted against treatment-resistant lung cancer, with a clinical trial expected to launch in Toronto and Zagreb, Croatia, later this year to evaluate one of them.
Feb 24, 2020
0
122
Researchers at Kanazawa University report in the Journal of Thoracic Oncology a promising novel approach for a combined treatment of the most common type of lung cancer and associated secondary cancers in the central nervous ...
Feb 7, 2020
0
1
Targeted, highly effective cancer treatments often produce debilitating side effects. This is the case with one commonly used therapy which works by blocking the epidermal growth factor receptor (EGFR), a protein that stimulates ...
Dec 12, 2019
0
68
No matter the pathogen—virus, bacterium or fungus—many "pick a specific type of lock" on the surface of cells, which allows the microbe to break and enter into the inner sanctum of the host's genome.
The relationship between gene alterations and response to anti-PD-L1 with and without anti-CTLA-4 are not well characterized. Dr. N. Rizvi from Columbia University Medical Center in New York today presented an update from ...
Sep 9, 2019
0
0
